American investment banking firm TD Cowen has reiterated its Buy rating on chipmaker Nvidia’s (NVDA) stock, stating it as, ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...

Investing.com -- TD Cowen lift its target on Mondelez (NASDAQ:MDLZ) International by $14 to $71, also raised its 2026 per share profit estimate, amid a 19% decline in cocoa spot prices this year ...

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030 ...

(Bloomberg) -- Microsoft Corp. has canceled some leases for US data center capacity, according to TD Cowen, raising broader concerns over whether it’s securing more AI computing capacity than it ...

On Thursday, TD Cowen initiated coverage on Disc Medicine (NASDAQ:IRON), giving the stock a Buy rating. Currently trading at $54.46, the company maintains a market capitalization of $1.83 billion ...

TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

The Washington-based software giant has canceled leases in the US totaling “a couple of hundred megawatts,” or about two huge data centers, according to a report from TD Cowen analysts ...

On Monday, TD Cowen adjusted its outlook on DraftKings Inc. (NASDAQ: NASDAQ:DKNG), elevating the price target to $60 from the previous $51, while reiterating a Buy rating for the company's shares.